Douglas Lyles

Cooley advised Advanced Instruments, a subsidiary of Patricia Industries and a manufacturer of analytical instruments for the biopharmaceutical and clinical markets, on intellectual property and licensing aspects in connection with its definitive agreement to acquire Nova Biomedical, a manufacturer of innovative analytical instruments and consumables that are vital in guiding the treatment of patients and the development of biotechnology therapeutics.

Cooley successfully lifted a Hatch-Waxman injunction for Liquidia Technologies, a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products, enabling Liquidia to launch its new drug, Yutrepia.

Cooley advised Adaptive Phage Therapeutics, a US-based, privately held, clinical-stage biotechnology company pioneering the development of phage-based therapies to combat bacterial infections, on its definitive merger agreement with BiomX, a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria.

Cooley advised Jackpocket, the first licensed third-party lottery courier app in the US, on its definitive agreement to be acquired by DraftKings for $750 million.

Cooley advised CallTower, an international leader in delivering cloud-based, enterprise-class communications, contact center and collaboration solutions, on its investment from BV Investment Partners.